Item Details

10 Nov 2026

Chinese Pharma Deal Reaches US$358 Million Upfront

On 6 November, Sino Biopharmaceutical signed a licensing agreement covering six preclinical cancer drugs with Boehringer Ingelheim. The upfront payment is US$358 million, with additional milestone payments possible. HPC can support pharmaceutical sourcing and healthcare-sector partnerships.

Get in Touch

We’ll get back to you shortly.